PURPOSE: In order to evaluate the feasibility of dose-dense @entity1205 followed by dose-dense AC ( @entity632 / @entity786 ) as adjuvant chemotherapy for operable @entity0 , we conducted a phase II study. @entity1 AND METHODS: In cohort 1, 28 @entity1 received @entity1205 100 mg/m2 followed by @entity632 60 mg/m2 with @entity786 600 mg/m2, each every 2 weeks for 4 weeks (total of 8 cycles). Enrollment was discontinued because of stopping criteria based on significant @entity137 (grade 4 hematologic @entity137 or grade >or= 3 nonhematologic @entity137 ). In cohort 2, the @entity1205 dose was reduced to 75 mg/m2; enrollment was discontinued after 18 @entity1 . RESULTS: Significant @entity137 occurred in 79% and 72% of @entity1 in cohorts 1 and 2, respectively, resulting in treatment delays in 50% and 17% of @entity1 , respectively. The most common grade 4 hematologic @entity137 was @entity1398 , which occurred in 7% and 42% of cohort 1 @entity1 during @entity1205 and AC, respectively, and in none and 19% of cohort 2 @entity1 , respectively. The most common grade >or= 3 nonhematologic @entity137 was @entity5515 , which occurred in 25% and none of cohort 1 @entity1 during @entity1205 and AC, respectively. With @entity1205 75 mg/m2 and @entity1 education encouraging routine use of topical strategies, grade 3 @entity5515 occurred in only 11% of cohort 2 @entity1 . Grade 2 nail changes were also debilitating and occurred in 33% of cohort 1 @entity1 during AC. CONCLUSION: These phase II findings suggest that dose-dense @entity1205 100 mg/m2 followed by AC is not feasible and, until more studies are conducted, should be restricted to clinical studies.

@entity137 of dose-dense @entity1205 followed by @entity632 with XXXX as adjuvant therapy for @entity0 in a phase II study.

@entity632 :: ('MESH:D004317', 'Chemical') :: ['doxorubicin'] @entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'PATIENTS'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer'] @entity786 :: ('MESH:D003520', 'Chemical') :: ['cyclophosphamide'] @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenia'] @entity1205 :: ('MESH:C067311', 'Chemical') :: ['docetaxel'] @entity5515 :: ('MESH:D017499', 'Disease') :: ['palmar-plantar erythrodysesthesia']
@entity786 :: (MESH:D003520,Chemical) :: ['cyclophosphamide']
